The inactivation of ERG3, a gene encoding sterol ⌬ 5,6 -desaturase (essential for ergosterol biosynthesis), is a known mechanism of in vitro resistance to azole antifungal drugs in the human pathogen Candida albicans. ERG3 inactivation typically results in loss of filamentation and attenuated virulence in animal models of disseminated candidiasis. In this work, we identified a C. albicans clinical isolate (VSY2) with high-level resistance to azole drugs in vitro and an absence of ergosterol but normal filamentation. Sequencing of ERG3 in VSY2 revealed a double base deletion leading to a premature stop codon and thus a nonfunctional enzyme. The reversion of the double base deletion in the mutant allele (erg3-1) restored ergosterol biosynthesis and full fluconazole susceptibility in VSY2, confirming that ERG3 inactivation was the mechanism of azole resistance. Additionally, the replacement of both ERG3 alleles by erg3-1 in the wild-type strain SC5314 led to the absence of ergosterol and to fluconazole resistance without affecting filamentation. In a mouse model of disseminated candidiasis, the clinical ERG3 mutant VSY2 produced kidney fungal burdens and mouse survival comparable to those obtained with the wild-type control. Interestingly, while VSY2 was resistant to fluconazole both in vitro and in vivo, the ERG3-derived mutant of SC5314 was resistant only in vitro and was less virulent than the wild type. This suggests that VSY2 compensated for the in vivo fitness defect of ERG3 inactivation by a still unknown mechanism(s). Taken together, our results provide evidence that contrary to previous reports inactivation of ERG3 does not necessarily affect filamentation and virulence. C andida spp. represent the fourth most common cause of nosocomial bloodstream infections in the United States, while displaying the highest or second highest crude mortality rates (11, 45) . Candida albicans generally remains the single most common opportunistic fungal pathogen worldwide (32). In the face of this, a rather limited number of chemical classes of antifungal drugs with different molecular targets are available for systemic use in the treatment of these infections. While echinocandins act at the cell wall level through noncompetitive inhibition of 1,3-␤-D-glucan synthesis after binding to Fks1p, other classes of drugs disturb the cell membrane's sterol composition. These sterol-related mechanisms of action are based either on direct binding to ergosterol, in the case of the polyene drugs (essentially amphotericin B), or on inhibition of the sterol biosynthetic pathway. For example, azoles inhibit Erg11p (14␣-lanosterol demethylase) but also Erg5p (sterol ⌬ 22 -desaturase). Allylamines, notably terbinafine, target Erg1p (squalene epoxidase), and the morpholine amorolfine inhibits Erg24p and Erg2p (sterol ⌬ 14 -reductase and ⌬ 8,7 -isomerase, respectively) (30).
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The generally effective and well-tolerated triazole drugs, particularly fluconazole, but also itraconazole and, more recently, voriconazole, are leading choices in the treatment of disseminated candidiasis (31) . Although considerably less significant than the case in bacteria, drug resistance in Candida spp. is an increasing problem, particularly with azole drugs, arising from long-term administration of these drugs for both treatment and prophylaxis of mycoses in susceptible patients (17) . Four different mechanisms of resistance to azole drugs have been described in detail for C. albicans, all based on altered gene expression and appearing to accumulate frequently in individual clinical isolates for stepwise development of high-level drug resistance (40) . The most commonly encountered is overexpression of multidrug efflux pump genes, namely, the ATP-binding cassette (ABC) transporter genes CDR1 and CDR2, and of the major facilitator gene MDR1 (with the product of the latter specifically transporting fluconazole only). Amino acid alterations in the target enzyme Erg11p, which lead to reduced affinity to azoles or altered enzyme kinetics, and overexpression of ERG11 are two additional mechanisms. Finally, a less common resistance mechanism is an alteration in the sterol biosynthetic pathway which results in the replacement of ergosterol by other sterols in the cytoplasmic membrane (40) . This mechanism consists mainly of the inactivation of the enzyme sterol ⌬ 5,6 -desaturase, encoded by ERG3, which catalyzes the introduction of a carbon-carbon double bond in the substrate molecules, one of the final steps in the ergosterol biosynthetic pathway. Erg3p is responsible for converting the nontoxic 14␣-methylated sterol intermediates accumulated due to azole activity, essentially 14␣-methylfecosterol, into the toxic sterol 14␣-methylergosta-8,24(28)-dien-3␤,6␣-diol. In this way, deletions of both ERG3 alleles in C. albicans lead to high-level azole resistance by allowing cells to bypass the synthesis of the toxic sterol (20, 44) .
This mechanism appears to be rather uncommon among azole-resistant C. albicans clinical isolates. Reported isolates include two strains from AIDS patients who had received fluconazole therapy for several years (20) and two strains isolated from leukemia patients following short-term fluconazole prophylaxis plus low-dose amphotericin B therapy (29) . An additional isolate, the Darlington strain, was obtained from a patient who had also been under prolonged azole exposure (26) , and two other clinical isolates were from the Schering-Plough Research Institute (Kenilworth, NJ) culture collection (5) . While no details are available regarding the specific mutations behind ERG3 inactivation in the first four strains, the Darlington strain is known to bear a nonsense mutation on one allele and three amino acid (aa) changes in the other, at least one of which allegedly inactivates the enzyme (26) . The two strains from the Schering-Plough Research Institute each display a specific homozygous nonsense mutation (5). Recently, four additional erg3 mutant clinical isolates were reported, although only two remained azole resistant when tested in the presence of a drug efflux inhibitor (23) . The other two contained substantial amounts of ergosterol in the membrane, corresponding to the so-called "leaky" erg3 mutants, a phenotype originally described for Saccharomyces cerevisiae (18) .
Besides these clinical isolates, a few laboratory-generated C. albicans erg3 mutants have been reported, either constructed through targeted deletion of both ERG3 alleles (25, 38) or, in one other case, obtained from serial cultures of a wild-type strain in the presence of fluconazole (46) . Typically, these erg3 mutants have lost the ability to produce hyphae. However, a report from Martel et al. described the first two filament-forming clinical erg3 mutants ever discovered (23) . Perhaps as a consequence of being locked in the yeast form, all isolates tested so far (not including the recent filament-forming mutants), irrespective of their clinical or in vitro origin, showed attenuated virulence in animal models of disseminated candidiasis (5, 25, 29) . Moreover, it has been suggested that despite the typical high-level in vitro resistance, ERG3 inactivity alone does not lead to fluconazole resistance in vivo (25) . This finding is rather surprising, particularly considering that in some cases such mutants have emerged in patients subjected to long-term azole exposure.
In this study, we describe additional ERG3 mutations in a C. albicans clinical isolate with high-level in vitro azole resistance and an altered membrane sterol profile (absence of ergosterol) but normal filamentation (unlike typical erg3 mutants). We further address whether ERG3 mutations have a negative impact on virulence and antifungal treatment with fluconazole in an animal model of disseminated candidiasis.
MATERIALS AND METHODS
Strains and media. The C. albicans strains used in this study are listed in Table 1 . The clinical isolate renamed VSY2 here corresponds to C. albicans H37, which was isolated from a bronchoalveolar lavage fluid sample at the Hospital S. João, Porto, Portugal, and kindly provided by Cidália PinaVaz. The strains were grown in liquid YEPD complete medium (1% Bacto peptone [Difco], 0.5% yeast extract [Difco], 2% glucose [Fluka] ). To grow the strains on solid medium, 2% agar (Difco) was added. Escherichia coli DH5␣ (15) was used as a host for plasmid construction and propagation. DH5␣ cells were grown in Luria-Bertani (LB) broth or on LB plates, which were supplemented with ampicillin (0.1 mg/ml) when required.
Drug susceptibility testing. Susceptibility assays were performed according to the standard broth microdilution protocols M27-A3 (Clinical and Laboratory Standards Institute [CLSI]) (6) and Edef. 7.1 (Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing [AFST-EUCAST]) (35) . Additional determinations were made for fluconazole in medium supplemented with 10% (vol/vol) fetal bovine serum (FBS; Sigma) or 20 g/ml of ergosterol (Sigma). Etest (bioMérieux) was performed according to the instructions of the manufacturer. For qualitative testing, yeast cultures were grown overnight in YEPD broth and diluted to a density of Efflux of R6G. A fluorescence rhodamine 6G (R6G) efflux assay with whole cells, adapted from a previously developed protocol (21) , was used to measure the drug efflux capacity of C. albicans strains. Briefly, cell cultures grown overnight in YEPD were diluted in 5 ml of fresh medium and allowed to grow at 30°C under constant agitation to a density of 2 ϫ 10 7 cells/ml. Cells were centrifuged, washed in 5 ml phosphate-buffered saline (PBS; pH 7), and resuspended in 2 ml PBS. These suspensions were incubated for 1 h at 30°C under constant agitation to deprive cells of energy, and R6G was next added at a concentration of 10 g/ml. The incubation was continued for 1 h to allow R6G accumulation. After this incubation time, cells were sedimented by centrifugation, washed with PBS at 4°C, and resuspended in a final volume of 300 l PBS. Fifty microliters of individual suspensions was diluted in 150 l PBS and aliquoted into a 96-well microtiter plate, which was then placed in a SpectraMax Gemini fluorometer (Molecular Devices, Sunnyvale, CA) with the temperature control set at 30°C. Baseline emission of fluorescence (excitation wavelength, 344 nm; emission wavelength, 555 nm) was recorded for 5 min, in relative fluorescence units (RFU), and D-glucose was next added to each strain, at a final concentration of 1% (wt/vol), to initiate R6G efflux. As negative controls, no glucose was added to a series of separate aliquots of each strain. Data points were recorded at 1-min intervals in duplicate for 60 min.
GC-MS sterol analysis. Nonsaponifiable lipids were extracted as reported previously (19) . Samples were dried in a vacuum centrifuge (Heto) and derivatized by the addition of 100 l 90% [N,O-bis(trimethylsilyl)trifluoroacetamide] (BSTFA)-10% trimethylchlorosilane (TMS) (Sigma) and 200 l anhydrous pyridine (Sigma) and heating for 2 h at 80°C. TMS-derivatized sterols were analyzed and identified using gas chromatography-mass spectrometry (GC-MS) (Agilent 5975C inert XL GC/MSD instrument), with reference to retention times and fragmentation spectra for known standards. GC-MS data files were analyzed using Agilent software (MSD Enhanced ChemStation; Agilent Technologies Ltd., Stockport, United Kingdom) to determine sterol profiles for all isolates and for integrated peak areas.
Germ tube production and biofilm formation. Cell suspensions from overnight YEPD cultures of C. albicans strains were washed in sterile saline solution and resuspended at a density of 5.0 ϫ 10 6 cells/ml in RPMI 1640 medium with and without 10% (vol/vol) FBS. The suspensions were incubated at 37°C with constant agitation, and samples from each suspension were visualized with a Zeiss Axioplan microscope. A DX30 digital camera with high resolution (Kappa Messtechnik GmbH, Gleichen, Germany) was used to record images. For biofilm formation, a method based on a published standardized protocol was followed (33) . Briefly, overnight yeast cultures in YEPD broth were washed twice in sterile PBS, resuspended in RPMI 1640 broth, and seeded in 96-well microtiter trays at a density of 10 6 cells/ml. The plates were sealed with Parafilm and incubated statically at 37°C. The plates were examined microscopically for the formation of biofilms after 24 h and 48 h.
Immunoblotting. Cell extracts for immunoblotting were prepared by an alkaline extraction procedure, as described previously (16), from C. albicans cells grown to mid-log phase in liquid YEPD at 30°C and from cells further treated with 20 g/ml of fluphenazine (Sigma) or 35 g/ml of benomyl (Sigma) for 30 min at 30°C in the same medium. Solubilized proteins (10 l) were separated by 10% SDS-PAGE and transferred by Western blotting onto a nitrocellulose membrane. Immunodetection of Cdr1p, Cdr2p, and Mdr1p was performed as previously described by chemiluminescence with an ECL kit (Amersham Biosciences), using polyclonal rabbit anti-Cdr1p, anti-Cdr2p (10), and anti-Mdr1p (16) antibodies, respectively.
Southern and Northern blots. Southern and Northern blotting, probe labeling with [␣-32 P]dATP, and signal reading and quantification were performed as described elsewhere (39) . The ERG3 probe for Southern blotting was located between the XbaI and XmnI restriction sites (positions Ϫ108 and ϩ448 relative to the ERG3 start codon). For Northern blots, samples of cells treated with fluphenazine and benomyl were included as described for immunoblotting. CDR1, CDR2, and MDR1 probes were generated as described previously (36, 39 ). An ACT1 probe was used as an internal control (7) .
Sequencing of ERG3. Genomic DNAs of C. albicans DSY294 and VSY2 were used as templates to amplify ERG3 by PCR using primers ERG3-Hi (5=-TTGTTAAGCTTTTTTTTCTTCCACCTATTTTG-3=) and ERG3-Ba (5=-CACACGGATCCATGTAACCCTTGATTC-3=). The resulting PCR products were purified using a QIAquick PCR purification kit (Qiagen Inc.), and 2.1-kb HindIII-BamHI fragments containing the ERG3 open reading frame (ORF) with 500-bp flanking regions were cloned into pBluescript II KS(ϩ) to yield pVS1 (ERG3 from DSY294) and pVS7 (ERG3 from VSY2, erg3-1). In order to exclude mutations due to PCR amplification and to determine both allele sequences, several recombinant plasmids were sequenced in addition to genomic DNA. Sequencing was performed using a BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems) according to the manufacturer's protocol.
Site-directed mutagenesis and isogenic strain collection. The double deletion at positions 120 and 121 on erg3-1 was reversed using a QuikChange II XL site-directed mutagenesis kit (Stratagene, Switzerland) according to the manufacturer's instructions. Plasmid pVS7, described above (containing erg3-1), was used as the template for PCR-mediated mutagenesis using primers VSY2-mut-rev-F (5=-GCTATACAATCATTTTCACAAATAGATTTC CCAAGTCTCCC-3=) and VSY2-mut-rev-R (5=-GGGAGACTTGGGAA ATCTATTTGTGAAAATGATTGTATAGC-3=), yielding pVS8, bearing the new revertant allele ERG3-2. A 0.56-kb fragment of the ERG3 3=-untranslated region (3=-UTR) immediately downstream of the 2.1-kb sequence described above was amplified from genomic DNA with primers ERG3-Not (5=-CGCGAAAGCGGCAGCCACGTGTGTGATGATCTGG-3=) and ERG3-SacI (5=-CGCGAAAGAGCTCGCATTTGAAAATGGATC GTGCG-3=), digested with NotI and SacI, and ligated into pDS1689 downstream of the SAT1 flipper cassette derived from pSFS1 (34), yielding pAC241. The two ERG3 alleles (erg3-1 and ERG3-2), flanked by 500-bp regions, were amplified from pVS7 and pVS8 by use of primers ERG3-Apa (5=-CGCGAAAGGGCCCTTGTTAAGCTTTTTTTTCTTCC ACC-3=) and ERG3-Xho (5=-CGCGAAACTCGAGTCACACAGATCCA TGTAACCCTTG-3=). The amplified alleles were digested with ApaI and XhoI and inserted upstream of the SAT1 flipper-ERG3 3=-UTR construct in pAC241 to obtain pVS9 (erg3-1) and pVS10 (ERG3-2). An isogenic strain collection was created by the SAT1 flipping method with linear constructs released from pVS9 and pVS10 by ApaI and SacI (approximately 7.4-kb fragments). The fragments were used to perform two rounds of transformation and excision of the SAT1 cassette in order to replace both original alleles. The erg3-1 construct was used to transform C. albicans SC5314, and the ERG3-2 construct was used to transform C. albicans SC5314 and VSY2 to obtain the complete collection shown in Table 1 . ERG3 sequences were confirmed for all strains, and integration at the correct genomic locus was verified by Southern blotting as described above (see Fig. S1 in the supplemental material).
Yeast transformation. The C. albicans strains were transformed by an adapted lithium acetate (LiAc) procedure (37) . After transformation with a linear DNA fragment, the cells were plated onto selective YEPD medium (with 200 g/ml of nourseothricin [clonNAT; Werner BioAgents]) and incubated for 2 to 3 days at 35°C. For FLP-mediated excision of the SAT1 cassette, cells were grown in YCB-BSA medium (23.4 g/liter yeast carbon base and 4 g/liter bovine serum albumin; pH 4.0) for 4 h at 35°C. Around 100 cells were then spread and grown for 48 h at 35°C on YPD plates containing 15 g/ml nourseothricin to select nourseothricin-sensitive strains.
Kidney fungal burden assay. Female 7-week-old BALB/c mice (approximately 20 g; Charles River Laboratories, France) were housed in filter-top cages with free access to food and water and were used for all in vivo experiments under the surveillance of the local governmental vet-erinarian offices (Affaires Vétérinaires du Canton de Vaud, Switzerland; authorization number 1734-3). C. albicans strains were grown to saturation in YPD medium at 30°C with agitation, diluted 200-fold in fresh YPD medium, and grown overnight under the same conditions. Overnight cultures were harvested, washed, and resuspended in sterile PBS at the desired concentrations. Inoculum concentrations were confirmed by counting CFU after plating serial dilutions onto YPD agar plates. To establish infection with each of the five yeast strains, 12 mice per strain were inoculated on day 0 of the experiment with 10 5 CFU (in 250 l of PBS) by intravenous injection in the lateral tail vein. Each group was then divided into two subgroups of six mice, one of which received intraperitoneal administration of 20 mg of fluconazole/kg of body weight once a day, starting 3 h after infection. To assess fungal burdens, mice were sacrificed on day 3 by CO 2 inhalation, and both kidneys were excised aseptically, weighed, and homogenized in PBS. Serial dilutions of the homogenates were plated onto YPD agar, and CFU numbers were used to determine CFU/g of kidney. Results were analyzed with the nonparametric Kruskal-Wallis test followed by pairwise comparisons between groups, using the software PASW Statistics 18. Differences were considered statistically significant when P values were below 0.05.
Mouse kidney histopathology analysis. Five groups of six mice were infected as described above for the kidney fungal burden assay, and kidneys were excised on day 3. One kidney from each mouse was used to determine kidney fungal burden as described above, and the other was fixed in a 4% formaldehyde solution in PBS. Several tissue sections were obtained from each kidney, stained with periodic acid-Schiff stain, and examined microscopically for morphology of C. albicans cells.
Mouse survival assay. The experimental setup for mouse survival assays was the same as that described above for the kidney fungal burden assay. Five groups of 7 mice were injected with 5 ϫ 10 5 CFU of each C. albicans strain on day 0 and then monitored daily until day 10. Survival rates were compared among groups by use of the log rank test with the software GraphPad Prism 5.0. Differences were considered statistically significant when P values were below 0.05.
Nucleotide sequence accession number. The nucleotide sequence for the erg3-1 allele was deposited in GenBank under accession number GU112753.
RESULTS

Phenotypic analysis of the clinical isolate VSY2.
The susceptibility profile of the clinical isolate VSY2 was investigated qualitatively using a visual spotting assay. The isolate displayed fluconazole resistance as shown by growth in medium including 5 or 10 g/ml of fluconazole (Fig. 1A) . Resistance was maintained when cyclosporine was added to the fluconazole-containing medium, and therefore the observed phenotype was not due to high growth trailing, which is otherwise suppressed in the presence of both drugs (22) . Fluphenazine hypersusceptibility was observed for the erg3⌬/⌬ mutant DSY1751 (corresponding to the targeted deletion of both ERG3 alleles and one ERG11 allele on the SC5314 strain background, using the "URA-blaster" method), but it was not detected in VSY2, although a difference in growth in comparison to the control was detectable (Fig. 1A) . These results were further confirmed with broth microdilution susceptibility testing. VSY2 displayed high-level azole resistance and a 2-fold elevation in the amphotericin B MIC value (Table 2) .
In order to verify drug extrusion, R6G efflux was measured in VSY2 and compared to that in the matched pair of strains DSY294 and DSY296, the latter of which is known to have a high R6G efflux capacity (8) . As illustrated in Fig. 2A , R6G efflux in VSY2 was only slightly higher than that in the azole-susceptible strain DSY294 and was clearly decreased compared to that in DSY296.
Background R6G efflux was measured in glucose-free yeast suspensions.
Northern blot analysis of multidrug transporter expression (Fig. 2B) showed the expected constitutive overexpression of CDR1 and CDR2 in DSY296 only, while the other test strains showed overexpression in response to fluphenazine exposure (an exception is the partial basal CDR1 overexpression in DSY1751). Overexpression of MDR1 was found in all cases exclusively following induction with benomyl (Fig. 2B) . DSY1751 showed decreased benomyl-induced MDR1 overexpression compared to the other tested strains. Taken together, these data suggest that azole resistance in VSY2 is not mediated by altered drug transport.
We therefore undertook the analysis of membrane sterols by GC-MS and observed from the resulting GC traces and MS fragmentation patterns (see Fig. S2 in the supplemental material) that VSY2 lacked the typical fungal sterol ergosterol and accumulated mainly ergosta-7,22-dienol and episterol ( Table 3) . As illustrated in Fig. 3 , this profile is consistent with the loss of ERG3 activity. A subsequent examination confirmed that VSY2 exhibited a normal transition to hyphae when incubated in the presence of serum, while no such morphological change occurred in the erg3⌬/⌬ mutant DSY1751 (Fig. 4) . Additionally, VSY2 was found to produce biofilms indistinguishable from those formed by the wild-type strain SC5314 (data not shown).
Sequencing of ERG3 from VSY2. Since VSY2 lacked detectable ergosterol and showed a sterol profile consistent with ERG3 inac- tivation, and although the strain displayed wild-type hyphal production, ERG3 alleles were sequenced from both the genomic DNA and cloned copies. Four homozygous alterations were identified compared to the wild-type sequence (from SC5314), including two silent point mutations (T51C and T434C), a double adenine deletion at the consecutive positions 120 and 121, and the missense mutation C1052T (A351V). The latter was previously reported for ERG3 from a wild-type strain (26) . Theoretically, the previously unreported homozygous double base deletion introduces a downstream frameshift mutation leading to an opal stop codon. In this way, ERG3 from VSY2 (which was named erg3-1) should translate into a truncated protein, incorporating only 51 of the 386 aa of the wild-type enzyme (and additionally displaying a sequence mismatch between aa 40 and 51).
Confirmation of the inactivity of erg3-1 from VSY2. In order to categorically confirm that the erg3-1 mutant allele is the genuine and sole mechanism behind altered sterol biosynthesis of VSY2 and high-level azole resistance, we used site-directed mutagenesis to revert the double-base-pair deletion at consecutive positions 120 and 121 in erg3-1, resulting in ERG3-2. Both the ERG3-2 and mutant erg3-1 alleles were introduced into SC5314 and VSY2 by replacing the original alleles at their native genomic locus (see Table 1 for strain descriptions). Ergosterol biosynthesis was restored in strain VSY20 (ERG3-2/ERG3-2 in the VSY2 background), as shown in Table 3 . Furthermore, VSY20 displayed full reversion of azole susceptibility in vitro (Table 2) , with production of trailing growth comparable to that of wild-type SC5314 or CAF2-1 when tested with fluconazole. VSY20 did not exhibit any noticeable changes in either the yeast-to-hypha transition (see Fig.  S3 in the supplemental material) or efflux pump expression, as deduced from immunoblotting analysis of Cdr1p, Cdr2p, and Mdr1p (see Fig. S4 ). Further corroboration was provided by the introduction of the mutated erg3-1 allele from VSY2 to replace both wild-type ERG3 alleles at their genomic locus in SC5314. The new strain, VSY18, displayed a typical erg3⌬/⌬ phenotype, with the absence of detectable ergosterol and the accumulation of ergosta-7,22-dienol (Table 3) , as well as resistance to azole drugs (Table 2) . It did, however, retain the ability to form filaments (see Fig. S3 ). Additionally, it showed similar results to those for VSY2 regarding susceptibility to fluphenazine, cycloheximide, and hygromycin B (Fig. 1A) . As expected, strain VSY19 (ERG3-2/ ERG3-2 in C. albicans SC5314) showed no noticeable phenotypic changes in comparison to the parent strain.
In vivo virulence assays. The lack of virulence of C. albicans erg3 mutants reported so far was assumed to be caused by the inability to undergo conversion from yeast to hyphae, which is a characteristic previously shown to be required for virulence in animal models of infection by C. albicans (41) . In this context, the idea that VSY2 could combine high-level azole resistance with intact virulence gained significance. In order to test this hypothesis, we injected the clinical and constructed strains into mice and assessed kidney fungal burdens after 3 days, with or without ad- (Fig. 5) . Fluconazole treatment resulted in a statistically significant decrease in CFU counts in all cases, with the exception of mice infected with the clinical mutant VSY2 (pairwise comparison P ϭ 0.075) (Fig. 5) . Also, the revertant strain on the VSY2 background, i.e., VSY20, showed a decreased response to fluconazole treatment compared to the other strains, although the response was still statistically significant (P ϭ 0.039). It was surprising that VSY20 (ERG3-2/ERG3-2 in the VSY2 background), which was fluconazole susceptible in vitro (fluconazole MIC ϭ 0.25 g/ml) ( Table 2) , exhibited an in vivo response to fluconazole treatment more similar to that of VSY2 than that of the other azole-susceptible strains (Fig. 5) . Regarding VSY2, the results demonstrate that this strain is azole resistant both in vitro and in vivo. It is therefore not likely that VSY2 can incorporate host sterols to compensate for the absence of ergosterol. This conclusion is supported by the high in vitro fluconazole MICs measured in the presence of FBS (which contains cholesterol, the mammalian homolog of ergosterol) ( Table 2 ). On the other hand, the addition of ergosterol resulted in a fluconazole MIC of 0.25 g/ml (Table 2) , although high trailing growth was observed (see Fig. S5 in the supplemental material). These results suggest that exogenous sterols are able to revert azole resistance in erg3 mutants. In order to confirm that VSY2 retained wild-type virulence, we then performed survival assays using the same strain collection. The results confirmed indistinguishable virulence between the wild-type strain SC5314 and VSY2 (log rank test [n ϭ 7 per group] P ϭ 0.5120) (Fig. 6) . A significant attenuation in virulence was found when the wild-type allele was replaced by erg3-1 in the SC5314 strain background (VSY18), suggesting that deletion of ERG3 attenuates virulence in this strain background (P ϭ 0.0246) (Fig. 6) . The difference was even larger between VSY18 (erg3-1/ erg3-1 in SC5314) and VSY2 (P ϭ 0.0010) (Fig. 6 ). There were no significant differences between the additional strains, including VSY20, corresponding to the reversion of the erg3-1 mutation in VSY2 (Fig. 6) . Histopathology of mouse kidney tissue sections stained with periodic acid-Schiff stain after infection with the C. albicans test strains revealed no noticeable differences in morphology. All strains, including VSY18 (erg3-1/erg3-1 in SC5314), were able to produce long hyphae in vivo, as observed 3 days after infection (see Fig. S6 ).
DISCUSSION
The erg3 mutant clinical C. albicans isolate described here (VSY2) shows the typical phenotypic profile for this mutation, including azole resistance and the absence of ergosterol (replaced by the accumulation of ergosta-7,22-dienol). A slight increase in amphotericin B MIC upon ERG3 inactivation was also detected in this strain. The fact that the increase was not more dramatic may be explained by well-known difficulties in detecting in vitro amphotericin B resistance. Generally, amphotericin B MICs measured by broth microdilution methods for Candida spp. appear tightly clustered between 0.25 and 1.0 g/ml, including those for isolates known to display clinical resistance. In fact, isolates showing MICs above 1.0 g/ml are considered likely to be resistant (6) . Etest revealed lower MIC values than those by broth microdilution, but it also resulted in a MIC increase for strains lacking functional ERG3 alleles. On the other hand, it has been suggested that these relatively low amphotericin B MICs for strains lacking ergosterol might also indicate the presence of additional amphotericin B cellular targets in C. albicans (38) . VSY2 diverged from expectations by not displaying the characteristic erg3 mutant hypersusceptibility to fluphenazine, a feature resulting in ERG3 mutants from alterations in membrane fluidity that cause enhanced drug permeability (38) . The same effect was observed in VSY18 (erg3-1/erg3-1 on the SC5314 strain background), while both strains did display hypersusceptibility to cycloheximide and hygromycin B. VSY2 also exhibited normal hyphal morphogenesis.
Comparison of VSY2 with other erg3 mutants. Clinical isolates of C. albicans with ERG3 mutations have rarely been detected, despite the high-level azole resistance resulting from the inactivation of this gene, thus contrasting with the large number of reported ERG11 mutations. A possible explanation is that these mutations most likely lead to additional, nonfavorable physiological changes, ultimately resulting in reduced fitness or virulence. In support of this hypothesis, all erg3 mutants tested so far, including clinical isolates and strains generated in vitro, exhibit attenuated virulence in animal models of infection (5, 25, 29) . In one case, two C. albicans strains isolated from leukemia patients following short-term fluconazole prophylaxis and low-dose amphotericin B therapy showed attenuated virulence in mouse survival assays (29) . These isolates were identified as erg3 mutants on the basis of their membrane sterol profiles, consistent with inactivation of ERG3, even if their ERG3 sequences have not been determined (29) . Two other clinical isolates with homozygous nonsense mutations in ERG3 (from the Schering-Plough Research Institute, Kenilworth, NJ) were found to produce similar kidney fungal burdens to those of wild-type strains in infected mice but attenuated virulence when survival was used as the endpoint (5). In that study, the authors used the laboratory-generated erg3 mutant strain DSY1751 as a positive control and found reduced virulence for this strain as well (5) . Finally, a report focusing on an erg3 strain generated using the "Ura-blaster" technique found both a significant reduction in kidney fungal burdens and attenuated virulence (25) . The URA3 positioning effect alone is known to influence the results of virulence studies. Reduced expression of Ura3p, an orotidine 5=-monophosphate decarboxylase, following ectopic expression of URA3 to complement uridine auxotrophy attenuates virulence in C. albicans (4) . However, in this case, the authors circumvented this situation by introducing a wild-type copy of URA3 at its native genomic locus before performing in vivo studies (25) . The data obtained with strain DSY1751 (erg3A⌬::hisG/erg3B⌬::hisG-URA3-hisG), on the other hand, were protected from the URA3 positioning effect by using the parent strain DSY1336 (erg3A⌬::hisG-URA3-hisG/ERG3), which showed higher virulence than that of DSY1751, as a control (5) .
Differentiated ability of erg3 mutants in the yeast-to-hypha transition. All previously tested erg3 mutants were unable to form filaments in vitro, while the referred laboratory-generated strain was additionally shown to be unable to form filaments in vivo (25) . Precisely, the lack of filamentation is believed to play a central role in the attenuation of virulence (5) . In fact, germ tube production has previously been found repeatedly to be required for virulence in animal models of invasive candidiasis (42) . The strict association between filamentation and virulence in C. albicans was challenged recently by the identification of several mutants from a library of homozygous deletion mutants with filamentation defects on solid Spider medium but intact virulence, as measured from kidney fungal burdens (28) . Several other mutants with normal filamentation but virulence defects were identified as well. However, the authors found that filamentation-defective mutants were likely to have decreased virulence, thus supporting an important role for filamentation in virulence in C. albicans (28) .
The clinical isolate VSY2 is the third reported erg3 mutant to conserve the ability to form filaments. Alterations in membrane composition arising from the replacement of ergosterol by alternative sterols in ERG3 mutants can affect membrane-localized proteins. As a consequence, they may interfere with many biological processes dependent on membrane-associated proteins, as seems to be the case with the signal transduction pathways regulating morphogenesis in C. albicans. Observations in S. cerevisiae erg3 mutants have further exposed mechanical consequences on membrane fluidity and water penetration into the membrane, specifically following fluconazole treatment (1). Moreover, sterols together with sphingolipids have been found to participate in the formation of polarized lipid rafts at hyphal tips during morphogenesis, and disturbance of these through alterations in membrane sterol composition most probably configures a mechanism of germ tube inhibition (2, 24) . Sterols and sphingolipids are in close interaction, and the sphingolipid composition is adapted by the cell following disturbances in sterol biosynthesis (14) . These reports provide support for the association between ERG3 inactivation and the inability to form filaments in C. albicans. VSY2 clearly deviates from this hypothesis, since it can form hyphae both in vitro and in vivo. This strain shows the characteristic membrane sterol composition of erg3 mutants, and filamentation might be promoted by some other mechanism(s) enabling the strain to bypass the specific signal transduction pathways regulating germ tube formation. VSY2 does not seem to utilize host-derived sterols to compensate for the lack of ergosterol. Such a possibility has been suggested for Candida glabrata ERG9 mutants, which could restore growth, probably by incorporating cholesterol from host tissues (27) . However, previous in vitro tests have revealed a difference between C. glabrata and C. albicans regarding cholesterol uptake, since only C. glabrata efficiently took up exogenous cholesterol (3, 43) . In agreement with these data, we found no influence of FBS on fluconazole resistance of our C. albicans strains in vitro, while supplementation with ergosterol did allow a reversion of resistance (Table 2 ). This suggests that C. albicans might be able to take up exogenous ergosterol while not being able to import its mammalian analogue (cholesterol). It must be kept in mind, however, that our data were obtained using a broth microdilution susceptibility assay, while previous studies with cholesterol used a qualitative spotting dilution assay (3, 43) .
The erg3 mutant clinical isolate VSY2 does not exhibit attenuated virulence. VSY2 could be the first C. albicans erg3 mutant ever reported to combine high-level azole resistance with intact virulence in vivo. We found the expected association between ERG3 inactivation and in vitro fluconazole resistance (Table 2) , but the in vivo results point to a more prominent role of the strain background rather than the ERG3 genotype. Survival experiments with murine models of disseminated candidiasis revealed the typical attenuation of virulence following ERG3 inactivation for the wild-type strain SC5314 but not for VSY2. Decreased virulence of strain VSY18 (erg3-1 alleles in the SC5314 strain background) supports the association between ERG3 inactivation and attenuated virulence, but VSY2 bypasses such virulence attenuation. This underscores the idea that cellular or genetic mechanisms may have developed in VSY2 to compensate for ERG3 inactivation and the associated decreased in vivo fitness. These mechanisms still operate after restoration of ERG3 activity in strain VSY20 (ERG3-2/ERG3-2 in VSY2 strain background; fluconazole MIC ϭ 0.25 g/ml) and lead to an in vivo response to fluconazole treatment resembling that of VSY2 rather than that of other in vitro fluconazole-susceptible strains. Like VSY2, two other recently reported strains might also be pathogenic C. albicans erg3 mutants, as the authors themselves suggested (23) . Nevertheless, in vivo experiments are necessary in order to test this hypothesis. The apparently limited dissemination of C. albicans erg3 mutants may well be associated with their attenuation in virulence. In fact, such isolates have only rarely been reported, even if they display highlevel resistance in vitro to the widely used azole drugs. The present results, together with the recent isolation of additional filamentforming erg3 mutants (23) , support the notion that C. albicans erg3 mutants may arise and bypass the expected filamentation defects and attenuation in virulence. Further studies on the specific alterations in the plasma membranes of such isolates allowing the conservation of filamentation and virulence in the absence of ergosterol biosynthesis are necessary.
